• Je něco špatně v tomto záznamu ?

Genetic Etiologies for Chronic Kidney Disease Revealed through Next-Generation Renal Gene Panel

AJ. Bleyer, M. Westemeyer, J. Xie, MS. Bloom, K. Brossart, JJ. Eckel, F. Jones, MZ. Molnar, W. Kotzker, P. Anand, S. Kmoch, Y. Xue, S. Strom, S. Punj, ZP. Demko, H. Tabriziani, PR. Billings, T. McKanna

. 2022 ; 53 (4) : 297-306. [pub] 20220324

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019493

INTRODUCTION: Chronic kidney disease (CKD) is a major public health issue in the USA. Identification of monogenic causes of CKD, which are present in ∼10% of adult cases, can impact prognosis and patient management. Broad gene panels can provide unbiased testing approaches, which are advantageous in phenotypically heterogeneous diseases. However, the use and yield of broad genetic panels by nephrologists in clinical practice is not yet well characterized. METHODS: Renal genetic testing, ordered exclusively for clinical purposes, predominantly by general and transplant nephrologists within the USA, was performed on 1,007 consecutive unique patient samples. Testing was performed using a commercially available next-generation sequencing-based 382 gene kidney disease panel. Pathogenic (P) and likely pathogenic (LP) variants were reported. Positive findings included a monoallelic P/LP variant in an autosomal dominant or X-linked gene and biallelic P/LP variants in autosomal recessive genes. RESULTS: Positive genetic findings were identified in 21.1% (212/1,007) of cases. A total of 220 positive results were identified across 48 genes. Positive results occurred most frequently in the PKD1 (34.1%), COL4A5 (10.9%), PKD2 (10.0%), COL4A4 (6.4%), COL4A3 (5.9%), and TTR (4.1%) genes. Variants identified in the remaining 42 genes comprised 28.6% of the total positive findings, including single positive results in 26 genes. Positive results in >1 gene were identified in 7.5% (16/212) of cases. CONCLUSIONS: Use of broad panel genetic testing by clinical nephrologists had a high success rate, similar to results obtained by academic centers specializing in genetics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019493
003      
CZ-PrNML
005      
20220804135713.0
007      
ta
008      
220720s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000522226 $2 doi
035    __
$a (PubMed)35325889
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bleyer, Anthony J $u Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
245    10
$a Genetic Etiologies for Chronic Kidney Disease Revealed through Next-Generation Renal Gene Panel / $c AJ. Bleyer, M. Westemeyer, J. Xie, MS. Bloom, K. Brossart, JJ. Eckel, F. Jones, MZ. Molnar, W. Kotzker, P. Anand, S. Kmoch, Y. Xue, S. Strom, S. Punj, ZP. Demko, H. Tabriziani, PR. Billings, T. McKanna
520    9_
$a INTRODUCTION: Chronic kidney disease (CKD) is a major public health issue in the USA. Identification of monogenic causes of CKD, which are present in ∼10% of adult cases, can impact prognosis and patient management. Broad gene panels can provide unbiased testing approaches, which are advantageous in phenotypically heterogeneous diseases. However, the use and yield of broad genetic panels by nephrologists in clinical practice is not yet well characterized. METHODS: Renal genetic testing, ordered exclusively for clinical purposes, predominantly by general and transplant nephrologists within the USA, was performed on 1,007 consecutive unique patient samples. Testing was performed using a commercially available next-generation sequencing-based 382 gene kidney disease panel. Pathogenic (P) and likely pathogenic (LP) variants were reported. Positive findings included a monoallelic P/LP variant in an autosomal dominant or X-linked gene and biallelic P/LP variants in autosomal recessive genes. RESULTS: Positive genetic findings were identified in 21.1% (212/1,007) of cases. A total of 220 positive results were identified across 48 genes. Positive results occurred most frequently in the PKD1 (34.1%), COL4A5 (10.9%), PKD2 (10.0%), COL4A4 (6.4%), COL4A3 (5.9%), and TTR (4.1%) genes. Variants identified in the remaining 42 genes comprised 28.6% of the total positive findings, including single positive results in 26 genes. Positive results in >1 gene were identified in 7.5% (16/212) of cases. CONCLUSIONS: Use of broad panel genetic testing by clinical nephrologists had a high success rate, similar to results obtained by academic centers specializing in genetics.
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetické testování $7 D005820
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    12
$a ledviny $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    12
$a chronická renální insuficience $x diagnóza $x genetika $7 D051436
655    _2
$a časopisecké články $7 D016428
700    1_
$a Westemeyer, Maggie $u Natera, Inc., San Carlos, California, USA
700    1_
$a Xie, Jing $u Natera, Inc., San Carlos, California, USA
700    1_
$a Bloom, Michelle S $u Natera, Inc., San Carlos, California, USA, mbloom@natera.com
700    1_
$a Brossart, Katya $u Natera, Inc., San Carlos, California, USA
700    1_
$a Eckel, Jason J $u North Carolina Nephrology Associates, Cary, North Carolina, USA
700    1_
$a Jones, Frederick $u North Carolina Nephrology Associates, Cary, North Carolina, USA
700    1_
$a Molnar, Miklos Z $u Division of Nephrology & Hypertension, Department of Medicine, University of Utah, Salt Lake City, Utah, USA
700    1_
$a Kotzker, Wayne $u Florida Kidney Physicians, Boca Raton, Florida, USA
700    1_
$a Anand, Prince $u MUSC Lancaster, Lancaster, South Carolina, USA
700    1_
$a Kmoch, Stanislav $u Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA $u Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Xue, Yuan $u Fulgent Genetics, Temple City, California, USA
700    1_
$a Strom, Samuel $u Fulgent Genetics, Temple City, California, USA
700    1_
$a Punj, Sumit $u Natera, Inc., San Carlos, California, USA
700    1_
$a Demko, Zachary P $u Natera, Inc., San Carlos, California, USA
700    1_
$a Tabriziani, Hossein $u Natera, Inc., San Carlos, California, USA
700    1_
$a Billings, Paul R $u Natera, Inc., San Carlos, California, USA
700    1_
$a McKanna, Trudy $u Natera, Inc., San Carlos, California, USA
773    0_
$w MED00000266 $t American journal of nephrology $x 1421-9670 $g Roč. 53, č. 4 (2022), s. 297-306
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35325889 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135706 $b ABA008
999    __
$a ok $b bmc $g 1822898 $s 1170736
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 53 $c 4 $d 297-306 $e 20220324 $i 1421-9670 $m American journal of nephrology $n Am J Nephrol $x MED00000266
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace